Pharma

February 06, 2024

Public Comment

Department of CommerceExecutive BranchHealthPharma

Civil Society Comment on the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights

Unfortunately, despite numerous petitions presented over the 40-plus year history of the Bayh-Dole Act, not once has a federal agency exercised its right to march-in and license competition to remedy price gouging (which constitutes a failure of the owner of a subject invention to make that invention available to the public on reasonable terms), or otherwise.

January 26, 2024

KJ Boyle

Blog Post Anti-MonopolyFTCPharma

The FTC Ain’t Nothin to Mess With

The FTC has won its lawsuit against Martin Shkreli, the pharmaceutical executive infamous for jacking up the price of the antiparasitic drug Daraprim from $13.50 to $750 overnight in 2015 and later using his ill-gotten fortune to buy an exclusive Wu-Tang Clan album for $2 million. Shkreli is the quintessential corporate ghoul, having already racked up convictions for securities fraud—which resulted in an indefinite ban from the securities industries—and failure to pay $1.26 million in New York state taxes. Now, his price gouging has finally caught up with him, as the FTC successfully argued that he spearheaded an anti-competitive scheme to monopolize the drug. The presiding judge found Shkreli’s conduct to be “egregious, deliberate, repetitive, long-running, and ultimately dangerous,” issuing a $64.6 million fine and imposing a lifetime ban from the pharmaceutical industry. 

September 01, 2023

Ananya Kalahasti Will Royce

Press Release Ethics in GovernmentHealthJudiciaryPharma

RELEASE: Judge Invested in Big Pharma Shouldn't Try Case on Big Pharma Profiteering

The Revolving Door Project’s Ananya Kalahasti and Will Royce released the following statement regarding the US Chamber of Commerce’s lawsuit regarding the Inflation Reduction Act’s Medicare prescription drug negotiation program, and a financial conflict of interest regarding the judge in the Southern District of Ohio.

July 26, 2022

Timi Iwayemi

Letter CoronavirusIntellectual PropertyPharma

Activists to Biden: Share Walter Reed Army Vaccine With the World

If the Walter Reed vaccine proves effective against Covid-19 and its variants in further tests, it will be a vaccine wholly created by a public institution through use of public funds. Every aspect of the vaccine production process should be widely and freely shared to ensure globally distributed manufacturing. Widespread, equitable availability of effective vaccines at truly affordable prices would go a long way in achieving your stated goal of vaccinating the world.

July 26, 2022

Timi Iwayemi

Press Release

CoronavirusIntellectual PropertyPharma

Advocates to President Biden: Don’t Give Away New Publicly-Owned Coronavirus Vaccine Technology to Corporations

In advance of the White House Summit on the Future of COVID-19 Vaccines today, 29 groups including Public Citizen, Demand Progress and Revolving Door Project, a project of the Center for Economic and Policy Research, sent a letter to President Joe Biden urging him to ensure that pan coronavirus vaccine technology currently under development by the U.S. military remain public, and shared with the world.

April 25, 2022 | The American Prospect

Max Moran Fatou Ndiaye

Op-Ed Congressional OversightPharma

Where's The Congressional Champion On Pharma Patent Abuses?

But for all of this, neither party’s congressional leaders have directly challenged the main legal mechanism that accounts for those high costs—namely, intellectual property. You’d think members of Congress would recognize the political salience of picking a fight with one of the most hated industries in America. So why isn’t anyone on Capitol Hill even talking about intellectual property’s role in driving high drug prices, and taking the PTO to task to do something about it?